全文获取类型
收费全文 | 744篇 |
免费 | 31篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 93篇 |
口腔科学 | 8篇 |
临床医学 | 30篇 |
内科学 | 274篇 |
皮肤病学 | 2篇 |
神经病学 | 84篇 |
特种医学 | 6篇 |
外科学 | 97篇 |
综合类 | 1篇 |
预防医学 | 9篇 |
眼科学 | 9篇 |
药学 | 16篇 |
中国医学 | 2篇 |
肿瘤学 | 134篇 |
出版年
2022年 | 4篇 |
2021年 | 9篇 |
2020年 | 4篇 |
2019年 | 4篇 |
2016年 | 5篇 |
2015年 | 10篇 |
2014年 | 6篇 |
2013年 | 19篇 |
2012年 | 23篇 |
2011年 | 25篇 |
2010年 | 6篇 |
2009年 | 12篇 |
2008年 | 21篇 |
2007年 | 30篇 |
2006年 | 18篇 |
2005年 | 25篇 |
2004年 | 32篇 |
2003年 | 30篇 |
2002年 | 25篇 |
2001年 | 31篇 |
2000年 | 35篇 |
1999年 | 44篇 |
1998年 | 11篇 |
1997年 | 11篇 |
1996年 | 9篇 |
1995年 | 6篇 |
1994年 | 9篇 |
1993年 | 7篇 |
1992年 | 26篇 |
1991年 | 21篇 |
1990年 | 22篇 |
1989年 | 26篇 |
1988年 | 18篇 |
1987年 | 25篇 |
1986年 | 27篇 |
1985年 | 34篇 |
1984年 | 12篇 |
1983年 | 9篇 |
1982年 | 4篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1978年 | 12篇 |
1977年 | 14篇 |
1976年 | 3篇 |
1975年 | 9篇 |
1974年 | 5篇 |
1973年 | 5篇 |
1972年 | 4篇 |
1969年 | 3篇 |
1967年 | 3篇 |
排序方式: 共有776条查询结果,搜索用时 15 毫秒
81.
Manometric and radiographic verification of esophageal body decompensation for patients with achalasia. 总被引:3,自引:0,他引:3
Y Shiino S G Houghton C J Filipi Z T Awad T Tomonaga R E Marsh 《Journal of the American College of Surgeons》1999,189(2):158-163
BACKGROUND: Although morphologic, radiographic, and manometric features of achalasia have been well defined, it has not been established by careful retrospective analysis whether achalasia is a progressive disorder resulting in complete decompensation. STUDY DESIGN: To verify the hypothesis that achalasia is a progressive disease, we retrospectively investigated manometric, radiographic, and symptomatic data in patients with achalasia. Sixty-three patients (36 women and 27 men) with a median age of 44 years (range 11 to 79 years) were evaluated. The duration of symptoms ranged from 1 to 442 months, with a median of 48 months. Patients were divided into four groups according to the duration of symptoms: 36 patients with less than 5 years, 11 with 5 to 10 years, 9 with 10 to 15 years, and 7 with 15 years or more. RESULTS: Contraction pressures of the esophageal body decreased significantly at every level when the duration of symptoms increased (p < 0.04). The percentage of simultaneous waves in the esophageal body rose as the duration of symptoms increased. All waves were synchronous in every patient who had had symptoms for more than 15 years. The maximal width of the esophageal body measured on esophagram became greater with an increase in the duration of symptoms, but this measurement did not reach statistical significance (p = 0.063). The tortuosity of the esophagus, measured by the maximal angle of the esophageal axis, was significantly greater in patients with a longer duration of symptoms (p < 0.02). The type of symptoms was not associated with the duration of symptoms. CONCLUSIONS: Achalasia is a progressive disease, as verified by manometric and radiographic findings. The classification of esophageal motor function expressed by amplitude of contraction pressure and angle of tortuosity is objective and useful. Classification of achalasia by duration of symptoms may be important in treatment selection and effectiveness. 相似文献
82.
83.
Tomonaga S Hayakawa T Yamane H Maemura H Sato M Takahata Y Morimatsu F Furuse M 《Nutritional neuroscience》2007,10(3-4):181-186
Carnosine (beta-alanyl-L-histidine) and its derivative anserine (beta-alanyl-1-methyl-L-histidine) are antioxidants and putative neurotransmitters in the brain. These dipeptides are rich in the commercially available supplement chicken breast extract (CBEX). To clarify the effects of CBEX on the brain, we examined whether single oral administration of CBEX (20 ml/kg) affects brain dipeptide and free amino acid concentrations in male Wistar rats. CBEX significantly and time-dependently increased carnosine and anserine levels in the plasma (at 120 min after injection, increase rates were 2976 and 4142%, respectively), hippocampus (64 and 78%), and hypothalamus (188 and 120%), but not in cerebral cortex. Significant and time-dependent increases in citrulline in the hippocampus (49%) and hypothalamus (41%) demonstrated generation of nitric oxide due to the increased carnosine and/or anserine levels in these brain regions. These findings suggest that CBEX modifies brain functions by increasing levels of these dipeptides. 相似文献
84.
Maeda T Murata K Fukushima T Sugahara K Tsuruda K Anami M Onimaru Y Tsukasaki K Tomonaga M Moriuchi R Hasegawa H Yamada Y Kamihira S 《International journal of hematology》2005,81(2):148-154
Blastic natural killer (NK) cell lymphoma corresponding to CD4+CD56+ malignancies is a novel disease entity, according to the results of clinical, morphologic, and immunologic studies. It is especially noteworthy that this disease likely arises from plasmacytoid dendritic cells (pDCs), described previously as plasmacytoid T-cells, which have an important role in innate and adaptive immunity. However, the exact relationship between the tumor cells and pDCs remains to be elucidated. We encountered a patient with typical blastic NK cell lymphoma, which later converted to leukemic manifestations, and tried to establish a cell line using the leukemic cells. We succeeded in establishment of a novel cell line, CAL-1, which originated from the primary malignant cells. The genetic and phenotypic features of CAL-1 cells bear a similarity to those of pDCs, namely, plasmacytoid morphology at light and electron microscopy; negative results for CD11c and lineage-associated markers of CD3, CD14, CD19, and CD16; positive results for HLA-DR, CD4, CD56, CD45RA, and CD123; and negative results for TCR and IgH gene rearrangements. An interesting finding was that CAL-1 cells change morphologically into the mature DC appearance with many long dendrites after short-term culture in the presence of granulocyte-macrophage colony-stimulating factor and interleukin 3. CAL-1 cells can secrete tumor necrosis factor alpha but not interferon alpha. Thus although they do not share in part phenotypic and functional features with their normal counterparts, CAL-1 cells mostly exhibit a striking pDC phenotype. We describe the first novel pDC cell line of CAL-1. This cell line should open the opportunity for study not only of CD4+CD56+ tumor cells but also of pDCs in vitro. 相似文献
85.
Kazuyuki Matsushita Kouichi Kitamura Bahityar Rahmutulla Nobuko Tanaka Takayuki Ishige Mamoru Satoh Tyuji Hoshino Satoru Miyagi Takeshi Mori Sakae Itoga Hideaki Shimada Takeshi Tomonaga Minoru Kito Yaeko Nakajima-Takagi Shuji Kubo Chiaki Nakaseko Masahiko Hatano Takashi Miki Masafumi Matsuo Masaki Fukuyo Atsushi Kaneda Atsushi Iwama Fumio Nomura 《Oncotarget》2015,6(7):5102-5117
86.
87.
Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes 总被引:8,自引:0,他引:8
Masako Iwanaga Koichi Furukawa Tatsuhiko Amenomori Hiroyuki Mori Hideo Nakamura Kengo Fuchigami Shimeru Kamihira Hideki Nakakuma & Masao Tomonaga 《British journal of haematology》1998,102(2):465-474
Among acquired stem cell disorders, pathological links between myelodysplastic syndromes (MDS) and aplastic anaemia (AA), and paroxysmal nocturnal haemoglobinuria (PNH) and AA, have been often described, whereas the relationship between MDS and PNH is still unclear. We analysed blood cells of patients with MDS to determine the incidence of the PNH clone, and analysed the PIG-A gene to find mutations characteristic of the PNH clone in MDS. In four (10%) of 40 patients with MDS, flow cytometry showed affected erythrocytes and granulocytes negative for decay-accelerating factor (DAF) and CD59. The population of affected erythrocytes was smaller in MDS patients with PNH clone (MDS/PNH) than in patients with de novo PNH, and haemolysis was milder in the MDS/PNH patients. PIG-A mutations were found in granulocytes of all patients with MDS/PNH. In type and site, the PIG-A mutations were heterogenous, similar to that observed in de novo PNH; i.e. no mutation specific to MDS/PNH was identified. Of note, three of four patients with MDS/PNH each had two PNH clones with different PIG-A mutations, suggesting that PIG-A is mutable in patients with MDS/PNH. In a MDS/PNH patient with trisomy 8, FISH detected a distinct karyotype in a portion of granulocytes with PNH phenotype, indicating that PNH and MDS partly shared affected cells. Thus, MDS predisposes to PNH by creating conditions favourable to the genesis of PNH clone. Considering the increasing prevalence and incidence of MDS, these disorders could be useful for investigating the mechanism by which PIG-A mutation is induced. 相似文献
88.
Ichikawa T Zhang J Chen K Liu Y Schopfer FJ Baker PR Freeman BA Chen YE Cui T 《Endocrinology》2008,149(8):4086-4094
89.
Kuriyama K Tomonaga M Kobayashi T Takeuchi J Ohshima T Furusawa S Saitoh K Ohno R;Japan Adult Leukemia Study Group 《International journal of hematology》2001,73(1):93-99
A morphological review system of the Japan Adult Leukemia Study Group has developed from the AML-87 through the AML-92 experience. We reviewed 1427 (90%) of 1592 cases enrolled in the AML-87, -89, or -92 protocols for morphology; 1408 (88%) were eligible. The rate of diagnostic concordance between each institute and the Committee on Morphological Diagnosis ranged from 76% to 80%. Acute myeloid leukemia (AML) subtypes were as follows: AML M0, 27 (2%); M1, 179 (13%); M2, 472 (34%); M3, 358 (25%); M4, 265 (19%); M5, 57 (4%); M6, 39 (3%); and M7, 11 (1%). The reason for the high number of patients with AML M3 is that many M3 patients were enrolled in the AML-92 protocol, which contained all-trans-retinoic acid. AML M0, M6 and M7 belonged to the poor prognostic groups. Auer bodies were found in 284 (53%) of 538 patients who survived significantly longer than those without Auer bodies in AML-87/-89. In AML-92 except for AML M3, 259 (43%) of 602 cases were Auer+ and also showed better survival rates. The survival of patients with >50% myeloperoxidase (MPO)-positive blast cells was better than those with < or =50% MPO+ blast cells in AML-87/-89. This trend was also seen in AML-92 excluding M3. AML with trilineage dysplasia (AML/TLD) is characterized as a subtype of de novo AML that shows morphological dysplasia of mature hematopoietic cells on a background of leukemic blast cells The number of patients with AML/TLD was 89 (16.5%) of 545 patients reviewed in AML-87/-89. AML-92, except for M3, showed a higher rate of patients with TLD (161 cases; 27.6%) because there were no patients with TLD in the AML M3 group. Survival rates for AML/TLD were worse than those for AML/non-TLD in both the AML-87/-89 and -92 protocols. Eighty percent of all cases (793/986) entered in AML-92 were analyzed cytogenetically. Fifty-one cases were not available for karyotyping because of a lack of mitoses or inappropriate preparations. The most frequent karyotype was normal, which accounted for 34.2%. The t(15;17), t(8;21), and inv(16) karyotypes, which are regarded as good risk factors, were 23.8%, 9.2%, and 1.6%, respectively. Abnormal chromosomes 5, 7, t(9;22), and t(6;9) were considered to be poor or intermediate risk factors As a new system of karyotyping begins in the ongoing AML protocol, useful chromosomal data will be obtained in the near future. 相似文献
90.
Tsukasaki K Tobinai K Shimoyama M Kozuru M Uike N Yamada Y Tomonaga M Araki K Kasai M Takatsuki K Tara M Mikuni C Hotta T;Lymphoma Study Group of the Japan Clinical Oncology Group 《International journal of hematology》2003,77(2):164-170
Aggressive adult T-cell leukemia-lymphoma (ATL) generally has a very poor prognosis. Deoxycoformycin (DCF, pentostatin), an inhibitor of adenosine deaminase, has shown promising therapeutic efficacy for ATL. To develop a new effective therapy against aggressive ATL, we carried out a multicenter phase II study of DCF-containing combination chemotherapy. Sixty-two previously untreated patients with ATL (34, 21, and 7 patients with diseases of the acute, lymphoma, and unfavorable chronic types, respectively) were enrolled, but 2 were ineligible because they were judged to be favorable chronic types. A regimen of 1 mg/m2 vincristine intravenously on days 1 and 8, 40 mg/m2 doxorubicin intravenously on day 1, 100 mg/m2 etoposide intravenously on days 1 through 3, 40 mg/m2 prednisolone orally on days 1 and 2, and 5 mg/m2 DCF intravenously on days 8, 15, and 22 was administered every 28 days for 10 cycles unless disease progression or toxic complications occurred. Fifty-two percent of 60 eligible patients responded (95% confidence interval [CI], 38%-65%), with 17 patients (28%) achieving a complete response (CR) (95% CI, 17%-41%) and 14 achieving a partial response. The CR rate was inferior to those of both the previous Japan Clinical Oncology Group (JCOG) study (JCOG8701, 43%), a 9-drug combination chemotherapy of the second generation, and the subsequent JCOG9303 study (35%), a granulocyte colony-stimulating factor-supported, dose-intensified, 9-drug regimen. The median survival time of the 60 eligible patients in JCOG9109 was 7.4 months, and the estimated 2-year survival rate was 15.5%; these results were identical with those of JCOG8701 but inferior to those of JCOG9303. Grade 4 neutropenia and infection of grade 3 or greater were frequent (67% and 22%, respectively), and treatment-related death was observed in 4 patients (7%), septicemia in 2, and cytomegalovirus pneumonia in 2. We conclude that DCF-containing combination chemotherapy is not a promising regimen against aggressive ATL. 相似文献